Editorials

It is time to adapt anti-CD20 administration schedule to allow efficient anti-SARS-Cov-2 vaccination in patients with lymphoid malignancies.

Service d’Hematologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, 78150, France; UVSQ, Inserm, CESP, 94805, Villejuif
Haematologica Early view Jul 29, 2021 https://doi.org/10.3324/haematol.2021.279457